The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...
The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...
Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...
Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...
Gastrointestinal (GI) Cancers Symposium, Dani Castillo, MD, medical oncologist, City of Hope, shared new research titled, “Impact of metastatic sites and Lauren subtype on survival outcomes of ...
Amid the many barriers to optimal influenza vaccination coverage, Marco del Riccio, MD, of the University of Florence in Italy, emphasizes the importance of prioritizing patients at the highest risk, ...
With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...
With the debut of TrumpRx.gov and other moves, the administration is steering the nation toward a market-driven, “America ...
Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...
Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...
With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback